BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

BioTime, Inc. 

1301 Harbor Bay Parkway

Alameda  California  94502  U.S.A.
Phone: 510-521-3390 Fax: 510-521-3389


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
BioTime (BTX) Subsidiary OncoCyte Corporation Completes Initial Enrollment Of Clinical Study Of Urine-Based Bladder Cancer Diagnostic 12/16/2014 11:48:21 AM
BioTime (BTX) Subsidiary ES Cell International Pte Ltd. And GE Healthcare Cross-License Patents In The Field Of Cell Assays For Drug Testing 12/16/2014 11:36:29 AM
BioTime (BTX) Subsidiary OncoCyte Corporation Completes Initial Enrollment Of Clinical Study Of Urine-Based Bladder Cancer Diagnostic 12/15/2014 10:08:35 AM
BioTime (BTX) Appoints Angus C. Russell To Board Of Directors 12/15/2014 8:42:44 AM
BioTime (BTX) To Host Investor And Analyst Day On December 15, 2014 12/15/2014 8:34:14 AM
LifeMap Sciences, A Subsidiary Of BioTime (BTX), Announces Release Of MalaCards Version 1.07 With Additional Types Of Clinical Significance From Clinvar And New Phenotypes From HPO 12/12/2014 10:30:54 AM
BioTime (BTX) To Present At The LD Micro VII Conference 12/4/2014 3:09:54 PM
BioTime (BTX) Reports Third Quarter Results And Recent Progress 11/10/2014 10:23:25 AM
BioTime (BTX) Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia™ In Europe 11/4/2014 10:37:22 AM
BioTime (BTX)’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization To Initiate Phase 1/2a Trial Of Embryonic Stem Cell-Derived Opregen® For The Treatment Of The Dry Form Of Age-Related Macular Degeneration 11/3/2014 12:19:14 PM
12345678910...